Adoram Therapeutics develops next-generation small molecule immunotherapies leveraging allosteric biochemistry — superior efficacy and safety over conventional orthosteric drugs for cancer, inflammation, and beyond.
Conventional drugs fight at the active site, losing to the body's natural ligands or causing off-target toxicity. Allosteric modulators bind elsewhere, enabling a new level of precision impossible with orthosteric approaches.
Dual-asset strategy with shared GPCR platform. A2AR NAM targets Ph Ib/combo exit in 2028/29; A2AR PAM targets DC nomination and out-licensing in 2026/27. A third undisclosed GPCR program in hit identification.
What sets allosteric modulation apart from every A2AR antagonist currently in clinical trials.
CHF 3.1M in non-dilutive grants secured. Seed 1st close complete. Seed 2nd close (CHF 1M) currently open via LEVA pooling. Series A targeting CHF 3.75M with multiple soft commitments.
Drug discovery scientists with clinical translation experience. Backed by a 12-person scientific and clinical advisory network from UNIGE, HUG, NYU Langone, IQVIA, and leading pharma (Novartis, Sanofi, Takeda, Amgen, Forbion).
We are securing investment to advance A2AR NAM to IND and first-in-human trials, nominate A2AR PAM as development candidate, and expand our allosteric pipeline via BD partnerships with pharma.